Glenmark Pharmaceuticals Toekomstige groei

Future criteriumcontroles 3/6

Glenmark Pharmaceuticals zal naar verwachting groeien in winst en omzet met respectievelijk 70.9% en 10.8% per jaar. De winst per aandeel zal naar verwachting groeien met 72.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 18.1% zijn.

Belangrijke informatie

70.9%

Groei van de winst

72.5%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	17.7%
Inkomstengroei	10.8%
Toekomstig rendement op eigen vermogen	18.1%
Dekking van analisten	Good
Laatst bijgewerkt	20 Jan 2025

Recente toekomstige groei-updates

Recent updates

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Dec 17

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Oct 26

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

May 28

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Feb 14

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05

Winst- en omzetgroeiprognoses

NSEI:GLENMARK - Toekomstschattingen van analisten en financiële gegevens uit het verleden (INR Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
3/31/2027	170,880	22,273	12,056	23,837	9
3/31/2026	152,376	17,873	9,017	19,647	12
3/31/2025	137,378	14,479	-4,562	6,179	12
9/30/2024	130,799	-10,183	-20,772	-13,441	N/A
6/30/2024	128,612	-15,732	N/A	N/A	N/A
3/31/2024	126,454	-18,990	-11,638	-2,654	N/A
12/31/2023	131,575	-7,640	N/A	N/A	N/A
9/30/2023	137,510	-1,263	302	7,192	N/A
6/30/2023	136,144	2,546	N/A	N/A	N/A
3/31/2023	116,556	-1,697	176	6,254	N/A
12/31/2022	126,355	8,811	N/A	N/A	N/A
9/30/2022	123,451	8,305	-21	7,689	N/A
6/30/2022	121,173	8,277	N/A	N/A	N/A
3/31/2022	123,049	9,417	3,185	11,087	N/A
12/31/2021	122,103	10,202	N/A	N/A	N/A
9/30/2021	118,248	10,464	5,411	12,490	N/A
6/30/2021	116,144	10,226	N/A	N/A	N/A
3/31/2021	109,439	9,700	3,565	11,312	N/A
12/31/2020	107,778	9,565	N/A	N/A	N/A
9/30/2020	107,445	8,992	3,945	12,296	N/A
6/30/2020	106,629	9,207	N/A	N/A	N/A
3/31/2020	106,573	7,760	4,610	13,924	N/A
12/31/2019	104,370	7,173	N/A	N/A	N/A
9/30/2019	102,564	6,428	1,271	13,254	N/A
6/30/2019	100,227	7,680	N/A	N/A	N/A
3/31/2019	98,655	9,250	870	13,242	N/A
12/31/2018	95,532	8,863	N/A	N/A	N/A
9/30/2018	92,018	8,721	N/A	N/A	N/A
6/30/2018	89,057	6,716	N/A	N/A	N/A
3/31/2018	90,744	8,039	N/A	16,481	N/A
12/31/2017	91,908	6,420	N/A	N/A	N/A
9/30/2017	95,055	10,083	N/A	N/A	N/A
6/30/2017	94,896	10,233	N/A	N/A	N/A
3/31/2017	90,794	9,160	N/A	6,574	N/A
12/31/2016	89,316	10,402	N/A	N/A	N/A
9/30/2016	81,749	7,508	N/A	N/A	N/A
6/30/2016	78,414	7,292	N/A	N/A	N/A
3/31/2016	75,732	7,021	N/A	3,448	N/A
12/31/2015	70,300	5,697	N/A	N/A	N/A
9/30/2015	69,530	5,141	N/A	N/A	N/A
6/30/2015	67,244	4,814	N/A	N/A	N/A
3/31/2015	65,561	4,753	N/A	4,817	N/A
12/31/2014	64,891	5,078	N/A	N/A	N/A
9/30/2014	63,983	6,092	N/A	N/A	N/A
6/30/2014	61,897	5,984	N/A	N/A	N/A
3/31/2014	59,450	5,423	N/A	8,537	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: Er wordt voorspeld dat GLENMARK de komende 3 jaar winstgevend zal worden, wat wordt beschouwd als een snellere groei dan de spaarquote ( 6.7% ).

Winst versus markt: Er wordt verwacht dat GLENMARK de komende 3 jaar winstgevend zal worden. Dit wordt gezien als een groei die boven het gemiddelde van de markt ligt.

Hoge groeiwinsten: Er wordt verwacht dat GLENMARK binnen 3 jaar winstgevend zal worden.

Omzet versus markt: De omzet van GLENMARK ( 10.8% per jaar) zal naar verwachting langzamer groeien dan de markt Indian ( 11% per jaar).

Hoge groei-inkomsten: De omzet van GLENMARK ( 10.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen GLENMARK zal naar verwachting over 3 jaar laag zijn ( 18.1 %).

Ontdek groeibedrijven

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2025/02/02 17:47
Aandelenkoers aan het einde van de dag	2025/02/01 00:00
Inkomsten	2024/09/30
Jaarlijkse inkomsten	2024/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .

Bronnen van analisten

Glenmark Pharmaceuticals Limited wordt gevolgd door 53 analisten. 12 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
null null	Anand Rathi Shares and Stock Brokers Limited
Ganeshram Jayaraman	Avendus Spark

Glenmark Pharmaceuticals Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 13% to ₹1,382

Price target increased by 9.7% to ₹1,056

Price target increased by 11% to ₹907

Price target increased by 12% to ₹689

Glenmark Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023

Consensus EPS estimates fall by 13%

Recent updates

Glenmark Pharmaceuticals Inc., USA Launches Phytonadione Injectable Emulsion USP, 10 Mg/Ml Single Dose Ampules

Is Glenmark Pharmaceuticals (NSE:GLENMARK) A Risky Investment?

Second quarter 2025 earnings released: EPS: ₹12.55 (vs ₹7.10 loss in 2Q 2024)

Glenmark Pharmaceuticals Limited to Report Q2, 2025 Results on Nov 14, 2024

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Glenmark Pharmaceuticals Limited Approves Dividend for the Year Ended March 31, 2024

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Dividend of ₹2.50 announced

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2024

Price target increased by 13% to ₹1,382

First quarter 2025 earnings released: EPS: ₹12.06 (vs ₹5.31 in 1Q 2024)

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Price target increased by 9.7% to ₹1,056

Full year 2024 earnings: EPS and revenues miss analyst expectations

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24

Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

Glenmark Pharmaceuticals Limited to Report Q4, 2024 Results on May 24, 2024

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Now 24% overvalued after recent price rise

Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) (GPL).

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Price target increased by 11% to ₹907

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2024 earnings released: ₹16.66 loss per share (vs ₹9.66 profit in 3Q 2023)

Glenmark Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Glenmark Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 10, 2023

Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-Morbidities

Glenmark Pharmaceuticals Receives ANDA Approval for Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg

Nirma Limited entered into a definitive agreement to acquire 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR 56.5 billion.

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals Divests 75% in GLS to Nirma

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited Announces Management Promotions

Upcoming dividend of ₹2.50 per share at 0.3% yield

Insufficient new directors

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

ChrysCapital Still in Race to Buy Controlling Stake in Glenmark Life Sciences

Price target increased by 12% to ₹689

First quarter 2024 earnings released: EPS: ₹5.31 (vs ₹6.82 in 1Q 2023)

Glenmark Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 11, 2023

Nirma, Sekhmet Pharmaventures Reportedly Vie for $731 Million Glenmark Life Stake

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Full year 2023 earnings released: EPS: ₹10.53 (vs ₹33.37 in FY 2022)

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-23

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Third quarter 2023 earnings released: EPS: ₹9.66 (vs ₹7.86 in 3Q 2022)

Glenmark Pharmaceuticals Limited Launches in India Unique I.V. Injection Formulation

Glenmark Pharmaceuticals Launches the Sacubitril + Valsartan Tablets in India for the Treatment of Heart Failure

Glenmark Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 10, 2023

Glenmark Pharmaceuticals Limited Receives Final Approval by United States Food & Drug Administration for Nicardipine Hydrochloride Capsules, 20 Mg and 30 Mg

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR3.1 billion.

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Glenmark Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

Glenmark Pharmaceuticals Limited to Launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, Having Comorbidities

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Glenmark Launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being